Contact
searchSearch
HMP Global
Login

Early Breast Cancer Specialty Channel

Early Breast Cancer
Specialty Channel
Robert Hills, DPhil
Conference Coverage
Upfront Surgical Resection Improves Outcomes for Older Patients With Early Breast Cancer
12/18/2024
Robert Hills, DPhil, discusses results from a meta-analysis which demonstrated that immediate surgical resection followed by either tamoxifen or tamoxifen alone significantly reduced long-term rates of progression, recurrence, and death for...
Robert Hills, DPhil, discusses results from a meta-analysis which demonstrated that immediate surgical resection followed by either tamoxifen or tamoxifen alone significantly reduced long-term rates of progression, recurrence, and death for...
Robert Hills, DPhil, discusses...
12/18/2024
Oncology
Conference Coverage
Optimal Therapy After Breast Conserving Surgery for Older Patients With Low-Risk Early Breast Cancer
12/03/2024
According to an interim analysis from a phase 3 trial, endocrine therapy significantly reduced health-related quality of life compared to radiation therapy among patients aged ≥70 year with luminal-like early breast cancer, following breast...
According to an interim analysis from a phase 3 trial, endocrine therapy significantly reduced health-related quality of life compared to radiation therapy among patients aged ≥70 year with luminal-like early breast cancer, following breast...
According to an interim analysis...
12/03/2024
Oncology
Conference Coverage
Omission of Sentinel Lymph Node Biopsy Among Clinically Node-Negative Patients With Early Invasive Breast Cancer
12/03/2024
According to results from the INSEMA trial, omitting sentinel lymph node biopsy resulted in a non-inferior invasive disease-free survival for clinically node-negative patients with early breast cancer.
According to results from the INSEMA trial, omitting sentinel lymph node biopsy resulted in a non-inferior invasive disease-free survival for clinically node-negative patients with early breast cancer.
According to results from the...
12/03/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
Sung Gwe Ahn, MD, PhD
Conference Coverage
Addition of Ovarian Function Suppression to Antihormonal Therapy Demonstrates Promise in HR-Positive, HER2-Positive Early Breast Cancer
10/31/2024
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses...
10/31/2024
Oncology
Conference Coverage
Using TIL Score to Predict Overall Survival, Guide Trastuzumab De-Escalation Among Patients With HER2-Negative Early Breast Cancer
10/23/2024
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the...
10/23/2024
Oncology
News
The TNBC-DX Test for Predicting pCR and Survival Outcomes Among Patients with Early-Stage Triple-Negative Breast Cancer
10/23/2024
The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.
The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.
The TNBC-DX, a novel genomic...
10/23/2024
Oncology
Conference Coverage
Addition of Durvalumab and Oleclumab to Standard SBRT and Neoadjuvant Chemotherapy Shows Clinical Promise Among Patients With ER-Positive, HER2-Negative Early Breast Cancer
10/23/2024
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the...
10/23/2024
Oncology
News
Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer
10/09/2024
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the...
10/09/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology

The Latest News

Robert Hills, DPhil
Conference Coverage
Upfront Surgical Resection Improves Outcomes for Older Patients With Early Breast Cancer
12/18/2024
Robert Hills, DPhil, discusses results from a meta-analysis which demonstrated that immediate surgical resection followed by either tamoxifen or tamoxifen alone significantly reduced long-term rates of progression, recurrence, and death for...
Robert Hills, DPhil, discusses results from a meta-analysis which demonstrated that immediate surgical resection followed by either tamoxifen or tamoxifen alone significantly reduced long-term rates of progression, recurrence, and death for...
Robert Hills, DPhil, discusses...
12/18/2024
Oncology
Conference Coverage
Optimal Therapy After Breast Conserving Surgery for Older Patients With Low-Risk Early Breast Cancer
12/03/2024
According to an interim analysis from a phase 3 trial, endocrine therapy significantly reduced health-related quality of life compared to radiation therapy among patients aged ≥70 year with luminal-like early breast cancer, following breast...
According to an interim analysis from a phase 3 trial, endocrine therapy significantly reduced health-related quality of life compared to radiation therapy among patients aged ≥70 year with luminal-like early breast cancer, following breast...
According to an interim analysis...
12/03/2024
Oncology
Conference Coverage
Omission of Sentinel Lymph Node Biopsy Among Clinically Node-Negative Patients With Early Invasive Breast Cancer
12/03/2024
According to results from the INSEMA trial, omitting sentinel lymph node biopsy resulted in a non-inferior invasive disease-free survival for clinically node-negative patients with early breast cancer.
According to results from the INSEMA trial, omitting sentinel lymph node biopsy resulted in a non-inferior invasive disease-free survival for clinically node-negative patients with early breast cancer.
According to results from the...
12/03/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
Sung Gwe Ahn, MD, PhD
Conference Coverage
Addition of Ovarian Function Suppression to Antihormonal Therapy Demonstrates Promise in HR-Positive, HER2-Positive Early Breast Cancer
10/31/2024
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses...
10/31/2024
Oncology
Conference Coverage
Using TIL Score to Predict Overall Survival, Guide Trastuzumab De-Escalation Among Patients With HER2-Negative Early Breast Cancer
10/23/2024
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the...
10/23/2024
Oncology
News
The TNBC-DX Test for Predicting pCR and Survival Outcomes Among Patients with Early-Stage Triple-Negative Breast Cancer
10/23/2024
The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.
The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.
The TNBC-DX, a novel genomic...
10/23/2024
Oncology
Conference Coverage
Addition of Durvalumab and Oleclumab to Standard SBRT and Neoadjuvant Chemotherapy Shows Clinical Promise Among Patients With ER-Positive, HER2-Negative Early Breast Cancer
10/23/2024
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the...
10/23/2024
Oncology
News
Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer
10/09/2024
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the...
10/09/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
Efstathios Kastritis, MD
Videos
Daratumumab Added to Standard Frontline AL Amyloidosis Treatment Demonstrates Improved Clinical Outcomes
01/15/2025
In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.
In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.
In the final analysis of the...
01/15/2025
Oncology
Christina Poh, MD
Videos
Tafasitimab Added to Lenalidomide and Ritixumab Shows Benefit for Patients With R/R FL
01/15/2025
The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitimab to...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
Charles Geyer, MD
Conference Coverage
Efficacy, Safety of Neoadjuvant/Adjuvant Atezolizumab for Patients With Triple-Negative Breast Cancer
01/14/2025
Charles Geyer, MD, discusses results from the phase 3 NSABP B-59/GBG-96-GeparDouze trial which assessed the efficacy of neoadjuvant atezolizumab and chemotherapy plus adjuvant atezolizumab in a cohort of patients with stage 2/3...
Charles Geyer, MD, discusses results from the phase 3 NSABP B-59/GBG-96-GeparDouze trial which assessed the efficacy of neoadjuvant atezolizumab and chemotherapy plus adjuvant atezolizumab in a cohort of patients with stage 2/3...
Charles Geyer, MD, discusses...
01/14/2025
Oncology

Quizzes

Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
Ribociclib Plus a Nonsteroidal Aromatase Inhibitor for HR-Positive, HER2-Negative Early Breast Cancer
11/08/2023
Which of the following statements about the results of the NATALEE study are true.
Which of the following statements about the results of the NATALEE study are true.
Which of the following...
11/08/2023
Oncology
Quiz
Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology
Quiz
For your patients with MF and anemia, which of the following would preclude you from initiating ruxolitinib at diagnosis?
12/13/2024
12/13/2024
Oncology
Quiz
You just diagnosed your patient with intermediate-1 primary MF. The patient has a spleen that is palpable 5 cm below the LCM; has mild disease-related symptoms; and is not anemic. What would you typically do next for a patient like this?
12/13/2024
12/13/2024
Oncology
Quiz
What is your primary treatment goal when treating your patients with MF?
12/13/2024
12/13/2024
Oncology
Quiz
At what baseline spleen size do you typically consider initiating treatment for a patient with MF who presents with mild to moderate symptoms?
12/13/2024
12/13/2024
Oncology
Quiz
While a target Hct level for patients with PV may be <45%, what is the maximum Hct level you would allow before changing your management approach?
12/12/2024
12/12/2024
Oncology
Quiz
Your PV patient is on their maximum tolerated dose of HU. At this point, what is the maximum Hct level you would allow before changing your management approach?
12/12/2024
12/12/2024
Oncology
Quiz
Managing for the risk of thrombosis is a key treatment goal for patients with PV. When it comes to managing for the risk of thrombosis, which counts are you most concerned about?
12/12/2024
12/12/2024
Oncology
Quiz
When it comes to managing for the risk of thrombosis, what is the maximum WBC count you would allow for your patients with PV?
12/12/2024
When it comes to managing for the risk of thrombosis, what is the maximum WBC count you would allow for your patients with PV?
When it comes to managing for the risk of thrombosis, what is the maximum WBC count you would allow for your patients with PV?
When it comes to managing for...
12/12/2024
Oncology
Quiz
Adjuvant Chemotherapy Plus Radiation for Patients With High-Risk Endometrial Cancer
11/26/2024
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year...
11/26/2024
Oncology

Recent News

Conference Coverage
Optimal Therapy After Breast Conserving Surgery for Older Patients With Low-Risk Early Breast Cancer
12/03/2024
According to an interim analysis from a phase 3 trial, endocrine therapy significantly reduced health-related quality of life compared to radiation therapy among patients aged ≥70 year with luminal-like early breast cancer, following breast...
According to an interim analysis from a phase 3 trial, endocrine therapy significantly reduced health-related quality of life compared to radiation therapy among patients aged ≥70 year with luminal-like early breast cancer, following breast...
According to an interim analysis...
12/03/2024
Oncology
Conference Coverage
Omission of Sentinel Lymph Node Biopsy Among Clinically Node-Negative Patients With Early Invasive Breast Cancer
12/03/2024
According to results from the INSEMA trial, omitting sentinel lymph node biopsy resulted in a non-inferior invasive disease-free survival for clinically node-negative patients with early breast cancer.
According to results from the INSEMA trial, omitting sentinel lymph node biopsy resulted in a non-inferior invasive disease-free survival for clinically node-negative patients with early breast cancer.
According to results from the...
12/03/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
Conference Coverage
Using TIL Score to Predict Overall Survival, Guide Trastuzumab De-Escalation Among Patients With HER2-Negative Early Breast Cancer
10/23/2024
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the...
10/23/2024
Oncology
News
The TNBC-DX Test for Predicting pCR and Survival Outcomes Among Patients with Early-Stage Triple-Negative Breast Cancer
10/23/2024
The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.
The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.
The TNBC-DX, a novel genomic...
10/23/2024
Oncology
Conference Coverage
Addition of Durvalumab and Oleclumab to Standard SBRT and Neoadjuvant Chemotherapy Shows Clinical Promise Among Patients With ER-Positive, HER2-Negative Early Breast Cancer
10/23/2024
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the...
10/23/2024
Oncology
News
Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer
10/09/2024
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the...
10/09/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer
07/17/2024
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study...
07/17/2024
Oncology
News
Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer
07/08/2024
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase...
07/08/2024
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use